Plain-English translation of NCT05708859 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether , a weekly injectable medication for diabetes, can slow down the buildup of plaque in your heart arteries. Half of the 120 participants will receive on top of their regular diabetes and heart medications, while the other half will receive a placebo (a dummy injection) for 12 months. Researchers will use special heart imaging scans to measure whether the medication slows plaque progression compared to placebo.
People with type 2 diabetes are at high risk for heart disease because plaque builds up in their arteries over time. Doctors want to know if this medication can help slow that dangerous plaque buildup and potentially prevent heart attacks and strokes.
You likely qualify if…
You likely don't qualify if…
You will visit the study site at baseline for heart imaging and blood tests to confirm you have coronary plaque. If you qualify, you will be randomly assigned to receive either the weekly injection or a placebo injection for 12 months. You will give yourself an injection once a week under your skin, keep taking your regular diabetes and heart medications at stable doses, and return for follow-up visits to monitor your health. At the end of 12 months, you will have another heart imaging scan to see if the medication slowed your plaque buildup.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Matthew J. Budoff
Collaborators
Eli Lilly and Company
Enrollment target
~120 participants
Started
January 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years – 80 Years
Last updated on clinicaltrials.gov in October 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sajad Hamal, MS
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.